CN104995184B - 作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物 - Google Patents

作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物 Download PDF

Info

Publication number
CN104995184B
CN104995184B CN201380068623.6A CN201380068623A CN104995184B CN 104995184 B CN104995184 B CN 104995184B CN 201380068623 A CN201380068623 A CN 201380068623A CN 104995184 B CN104995184 B CN 104995184B
Authority
CN
China
Prior art keywords
compound
cancer
reaction
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380068623.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104995184A (zh
Inventor
洪庸莱
罗贞恩
闵任淑
车贤珠
权璱基
卢成求
曹重明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CrystalGenomics Inc
Original Assignee
CrystalGenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CrystalGenomics Inc filed Critical CrystalGenomics Inc
Publication of CN104995184A publication Critical patent/CN104995184A/zh
Application granted granted Critical
Publication of CN104995184B publication Critical patent/CN104995184B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380068623.6A 2012-12-28 2013-12-26 作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物 Active CN104995184B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746980P 2012-12-28 2012-12-28
US61/746,980 2012-12-28
PCT/KR2013/012204 WO2014104757A1 (ko) 2012-12-28 2013-12-26 Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물

Publications (2)

Publication Number Publication Date
CN104995184A CN104995184A (zh) 2015-10-21
CN104995184B true CN104995184B (zh) 2018-01-02

Family

ID=51021712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380068623.6A Active CN104995184B (zh) 2012-12-28 2013-12-26 作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物

Country Status (15)

Country Link
US (4) US9758508B2 (OSRAM)
EP (2) EP3428161B1 (OSRAM)
JP (2) JP6325573B2 (OSRAM)
KR (1) KR102009163B1 (OSRAM)
CN (1) CN104995184B (OSRAM)
AU (3) AU2013371146C1 (OSRAM)
BR (1) BR112015015477B1 (OSRAM)
CA (1) CA2896711C (OSRAM)
DK (1) DK2940014T3 (OSRAM)
ES (2) ES2929906T3 (OSRAM)
MX (2) MX2021011563A (OSRAM)
PL (1) PL2940014T3 (OSRAM)
PT (1) PT2940014T (OSRAM)
RU (2) RU2018138028A (OSRAM)
WO (1) WO2014104757A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
ES2929906T3 (es) 2012-12-28 2022-12-02 Crystalgenomics Inc Derivado de 2,3-dihidro-isoindol-1-ona como supresor de cinasa BTK, y composición farmacéutica que lo incluye
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018156578A1 (en) * 2017-02-21 2018-08-30 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3886840A4 (en) * 2018-11-30 2022-08-24 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN116829143A (zh) * 2021-01-05 2023-09-29 住友制药肿瘤公司 非受体型酪氨酸激酶1(tnk1)抑制剂的形式和制剂
JP2024509192A (ja) * 2021-03-05 2024-02-29 ニンバス サターン, インコーポレイテッド Hpk1アンタゴニスト及びその使用
JP2024513011A (ja) 2021-03-29 2024-03-21 ニンバス サターン, インコーポレイテッド Hpk1アンタゴニスト及びその使用
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
CN101410391A (zh) * 2006-03-20 2009-04-15 霍夫曼-拉罗奇有限公司 2,3-二氮杂萘酮吡唑衍生物、它们的制备及作为药剂的应用
CN101835755A (zh) * 2007-10-23 2010-09-15 霍夫曼-拉罗奇有限公司 新型激酶抑制剂
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157873A0 (en) * 2001-04-12 2004-03-28 Hoffmann La Roche DIHYDRO-BENZO [b] [1,4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
WO2004108672A1 (en) * 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
WO2006112479A1 (ja) * 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
WO2012014017A1 (en) 2010-07-30 2012-02-02 Poly Medicure Limited Catheter introducer
ES2929906T3 (es) * 2012-12-28 2022-12-02 Crystalgenomics Inc Derivado de 2,3-dihidro-isoindol-1-ona como supresor de cinasa BTK, y composición farmacéutica que lo incluye
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
CN101410391A (zh) * 2006-03-20 2009-04-15 霍夫曼-拉罗奇有限公司 2,3-二氮杂萘酮吡唑衍生物、它们的制备及作为药剂的应用
CN101835755A (zh) * 2007-10-23 2010-09-15 霍夫曼-拉罗奇有限公司 新型激酶抑制剂
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
US9758508B2 (en) 2017-09-12
BR112015015477A2 (pt) 2017-07-11
BR112015015477B1 (pt) 2022-07-12
AU2013371146A1 (en) 2015-07-16
AU2020201431A1 (en) 2020-03-19
WO2014104757A1 (ko) 2014-07-03
KR102009163B1 (ko) 2019-08-09
EP3428161B1 (en) 2022-09-07
CA2896711A1 (en) 2014-07-03
PT2940014T (pt) 2018-11-28
JP2018109069A (ja) 2018-07-12
RU2671847C2 (ru) 2018-11-07
EP2940014A1 (en) 2015-11-04
AU2018214134A1 (en) 2018-08-30
AU2013371146B2 (en) 2018-05-10
EP2940014A4 (en) 2016-06-22
US20210009565A1 (en) 2021-01-14
PL2940014T3 (pl) 2019-03-29
MX2015008396A (es) 2016-04-15
KR20160058720A (ko) 2016-05-25
AU2013371146C1 (en) 2019-01-17
EP3428161A1 (en) 2019-01-16
ES2929906T3 (es) 2022-12-02
RU2018138028A (ru) 2019-03-21
MX386542B (es) 2025-03-18
CA2896711C (en) 2019-12-31
US20220380346A1 (en) 2022-12-01
AU2018214134B2 (en) 2020-03-12
US20150336934A1 (en) 2015-11-26
EP2940014B1 (en) 2018-09-26
DK2940014T3 (en) 2018-12-10
RU2015124381A (ru) 2017-02-01
HK1259355A1 (en) 2019-11-29
US11230539B2 (en) 2022-01-25
AU2020201431B2 (en) 2021-07-22
CN104995184A (zh) 2015-10-21
JP6325573B2 (ja) 2018-05-16
US20170362205A1 (en) 2017-12-21
US10604508B2 (en) 2020-03-31
JP2016504351A (ja) 2016-02-12
ES2696700T3 (es) 2019-01-17
MX2021011563A (es) 2022-10-10
JP6596537B2 (ja) 2019-10-23

Similar Documents

Publication Publication Date Title
CN104995184B (zh) 作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物
KR101652229B1 (ko) 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
AU2018301681B2 (en) NLRP3 modulators
JP2019503395A (ja) ピロロピリミジン5員環アザ環状誘導体およびその利用
EA022527B1 (ru) 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ
TW202132307A (zh) 雜環rip1抑制性化合物
WO2014082578A1 (zh) 杂芳基炔烃化合物及其应用
CN114031559A (zh) 基于芳基含氮杂环修饰的5-氟-嘧啶二胺苯甲酸酯及其制备方法与应用
CN113214230B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
CN112250672B (zh) 一种核苷碱基衍生物及其制备方法和应用
HK1259355B (en) 2,3-dihydro-isoindole-1-one derivative as btk kinase suppressant, and pharmaceutical composition including same
JP2004115458A (ja) 2−(3−ニトロベンゾイル)安息香酸誘導体を有効成分とする医薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant